About this trial
The DOME study is a clinical trial exploring a new treatment approach for patients who suffered a severe brain bleed due to an aneurysm.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 years or older
CT confirmed aSAH with an angiographically detected aneurysm
World Federation of Neurological Sciences (WFNS) aSAH grade 3-5 aneurysm
LAR available and gives consent within 72 hours after the onset of aSAH (or last known normal
Disqualifiers
Patients whose aneurysm judged appropriate for balloon-assisted coiling
Patients whose aneurysm is bleeding from the "neck"
Patients who are clinically judged to suffer imminent death within 24 hours.
Pregnancy or positive urine pregnancy test
Trial population
Patients 18 years or older with CT confirmed aSAH with an angiographically detected aneurysm
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Re-rupture incidence
Detected on head CT
Secondary outcomes
Functional Outcome
Measured on Modified Rankin Scale (MRS) Scored 0-6 where 0-No disability, 1=no significant disability, 2= slight disability, 3=moderate disability, 4=moderately severe disability, 5=severe disability, 6=dead. The higher the score the worse the outcome.
Accomplishment of Dome protection
Based on angiographic goals: 1) partial coil obliteration of the aneurysm dome or increased contrast stasis within the aneurysm dome compared to pre-embolization angiography, 2) filling of the aneurysm neck, 3) no filling of the aneurysm dome wall, and 4) no filling of the aneurysm rupture site or extra-aneurysmal contrast extravasation.
Procedural complications during the dome-protection and delayed final procedures on the aneurysm
Collection of adverse events.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.